EXHIBIT 99.1
Relmada Therapeutics, Inc.
Proforma Balance Sheet
March 31, 2019
Unaudited
| March 31, 2019 | ||||||||||||
| Without Impact of Financings | Pro Forma Adjustments Resulting from Financings | Post Pro- Forma Adjustments | ||||||||||
| ($ in thousands) | ||||||||||||
| Assets: | ||||||||||||
| Current | $ | 2,330,300 | $ | 10,855,700 | a | $ | 13,186,000 | b | ||||
| Non-current | 273,427 | - | 273,427 | |||||||||
| Total assets | 2,603,727 | 10,855,700 | 13,459,427 | |||||||||
| Liabilities and stockholders’ equity: | ||||||||||||
| Current | 2,129,829 | - | 2,129,829 | |||||||||
| Non-current | - | - | - | |||||||||
| Total Liabilities | 2,129,829 | - | 2,129,829 | |||||||||
Stockholders’ equity | 473,898 | 10,855,700 | 11,329,598 | |||||||||
| Total liabilities and stockholders’ equity | $ | 2,603,727 | $ | 10,855,700 | $ | 13,459,427 | ||||||
| (a) | This is the adjustment to account for the net proceeds from the financing transactions that occurred on 5/14/19, 6/14/2019, 6/20/19 and 6/28/2019 |
| (b) | This is the proforma Balance sheet as if the net proceeds from the financing transactions (noted above) had happened on 3/31/2019 |